<?xml version="1.0"?>
<?xml-stylesheet type="text/xsl" href="billres.xsl"?>
<!DOCTYPE bill PUBLIC "-//US Congress//DTDs/bill.dtd//EN" "bill.dtd">
<bill bill-stage="Introduced-in-Senate" dms-id="A1" public-private="public">
	<metadata xmlns:dc="http://purl.org/dc/elements/1.1/">
<dublinCore>
<dc:title>114 S2443 IS: Advancing Standards in Regenerative Medicine Act</dc:title>
<dc:publisher>U.S. Senate</dc:publisher>
<dc:date>2016-01-12</dc:date>
<dc:format>text/xml</dc:format>
<dc:language>EN</dc:language>
<dc:rights>Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.</dc:rights>
</dublinCore>
</metadata>
<form>
		<distribution-code display="yes">II</distribution-code>
		<congress>114th CONGRESS</congress><session>1st Session</session>
		<legis-num>S. 2443</legis-num>
		<current-chamber>IN THE SENATE OF THE UNITED STATES</current-chamber>
		<action>
			<action-date date="20160112">January 12, 2016</action-date>
			<action-desc><sponsor name-id="S354">Ms. Baldwin</sponsor> introduced the following bill; which was read twice and referred to the <committee-name committee-id="SSHR00">Committee on Health, Education, Labor, and Pensions</committee-name></action-desc>
		</action>
		<legis-type>A BILL</legis-type>
		<official-title>To support the establishment of a Standards Coordinating Body  in Regenerative Medicine and
			 Advanced Therapies.</official-title>
	</form>
	<legis-body>
		<section id="S1" section-type="section-one"><enum>1.</enum><header>Short title</header>
 <text display-inline="no-display-inline">This Act may be cited as the <quote><short-title>Advancing Standards in Regenerative Medicine Act</short-title></quote>.</text>
		</section><section id="id18E8578715054688A38F1D81FA00CC90"><enum>2.</enum><header>Support for the establishment of a standards coordinating body in regenerative medicine and
 advanced therapies</header><text display-inline="no-display-inline">Subchapter A of chapter V of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/351">21 U.S.C. 351 et seq.</external-xref>) is amended by inserting after section 506F the following:</text>
			<quoted-block display-inline="no-display-inline" id="id57065F13A0F44DA0BD94E97CC810B5B0" style="OLC">
				<section id="idFC40C9434DA34B8DA86515DE1A4AFF4E"><enum>506G.</enum><header>Coordinating body in regenerative medicine and advanced therapies</header>
 <subsection id="id98B3C5F56A7B49F78A2972147F8D0CF6"><enum>(a)</enum><header>In general</header><text>The Secretary, in consultation with stakeholders, including regenerative medicine product manufacturers and clinical trial sponsors, contract manufacturers, academic institutions, standard setting organizations, the National Institute of Standards and Technology, and other relevant Federal agencies, as appropriate, shall facilitate establishment of a public-private Standards Coordinating Body in Regenerative Medicine and Advanced Therapies.</text>
 </subsection><subsection id="id192F5F8C1D544A18B61899E54572B1F9"><enum>(b)</enum><header>Function of standards coordinating body</header><text>Upon establishment of the Standards Coordinating Body in Regenerative Medicine and Advanced Therapies under subsection (a), the Secretary shallâ€”</text>
 <paragraph id="idCEE9E44E458C47B2AE2D7B5E215570D5"><enum>(1)</enum><text>identify opportunities for the development of laboratory regulatory science research and documentary standards that the Secretary determines would support the development, evaluation, and review of regenerative medicine products; and</text>
 </paragraph><paragraph id="idEAC42F5AB369421D86ED26077790CE6C"><enum>(2)</enum><text>work with such Standards Coordinating Body, as appropriate, in the development of standards described in paragraph (1).</text>
 </paragraph></subsection><subsection id="idAE4658A73AFD416EB18442BAC6309161"><enum>(c)</enum><header>Guidance</header><text>The Secretary shall issue guidance, as appropriate, on how standards may be used in regulatory review for regenerative medicine and advanced therapies.</text>
 </subsection><subsection id="idFDE72938A31A40CEB67B3DD9260EB5A7"><enum>(d)</enum><header>Definition</header><text>For purposes of this section, the term <term>regenerative medicine and advanced therapies</term> includes cell therapy, gene therapy, gene-modified cell therapy, therapeutic tissue engineering products, and human cell and tissue products, and combination products using any such therapies or products.</text>
 </subsection><subsection id="id1EBB6BBB69284922BE31B21EE458F398"><enum>(e)</enum><header>No additional funds</header><text>The Secretary shall carry out this section using funds otherwise made available to the Food and Drug Administration. No additional funds are authorized to be appropriated to carry out this section.</text></subsection></section><after-quoted-block>.</after-quoted-block></quoted-block>
		</section></legis-body>
</bill>


